For example, metformin’s AMPK-dependent effects inhibit aromatase, thereby inhibiting androgen to estrogen conversion, and statins inhibit cholesterols—necessary for estrogen synthesis—along the mevalonate pathway, which is also dysregulated in certain breast cancer subtypes [4, 5, 21–23]. This evidence concerns the gene CYP19A1 and breast carcinoma.